Avacta claimed that Optim fills a significant gap in the market by providing detailed analysis using only very small sample volumes, and also enables drug developers to gain vital information about product performance in the earliest stages of product development, when very limited quantities of material are available, helping to reduce the risk of later stage failure.
Avacta’s latest order, which brings the total number of orders to six with three units installed and a further unit due to ship within weeks, was secured by Isogen the recently appointed European distributor.
Avacta CEO Alastair Smith said that the latest Optim order from a biopharmaceutical developer is clearly an important sale.
"I am particularly pleased that by running a short evaluation of Optim for the customer using their test samples the sale was quickly secured, which is an indictment of the value proposition of Optim," Smith said.